{"id":"methotrexate-monotherapy","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"5-20","effect":"Mucositis / stomatitis"},{"rate":"10-25","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Alopecia"},{"rate":"5-20","effect":"Infection"},{"rate":"5-15","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:34:47.940705","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits the enzyme dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions in nucleotide synthesis. This leads to decreased DNA and RNA synthesis, resulting in reduced cell proliferation. At lower doses used in autoimmune conditions, it also has immunosuppressive and anti-inflammatory effects through adenosine release and other mechanisms.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:45.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Crohn's disease"}]},"_fixedFields":["pubmed(254)"],"trialDetails":[{"nctId":"NCT06496178","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Merus B.V.","startDate":"2024-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":500},{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT07428551","phase":"PHASE4","title":"Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2024-03-01","conditions":"Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Refractory Polyarticular Juvenile Idiopathic Arthritis","enrollment":50},{"nctId":"NCT03852888","phase":"NA","title":"Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2018-11-14","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT04483466","phase":"PHASE3","title":"Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"George Washington University","startDate":"2023-07-18","conditions":"Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity","enrollment":150},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT06530576","phase":"PHASE2","title":"Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-10","conditions":"T-LGL Leukemia, NK-LGL Leukemia","enrollment":48},{"nctId":"NCT04947319","phase":"PHASE2","title":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-12-29","conditions":"Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma","enrollment":119},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT06918886","phase":"","title":"Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments","status":"NOT_YET_RECRUITING","sponsor":"Bezmialem Vakif University","startDate":"2025-04-10","conditions":"Psoriatic Arthritis (PsA), Liver Fibrosis, Liver Diseases","enrollment":90},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03505008","phase":"PHASE4","title":"Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan","status":"COMPLETED","sponsor":"Keio University","startDate":"2018-04-18","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05616871","phase":"","title":"An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-12-15","conditions":"Psoriatic Arthritis","enrollment":450},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT04914741","phase":"PHASE1, PHASE2","title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-06-29","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":80},{"nctId":"NCT04772313","phase":"PHASE4","title":"Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-03-08","conditions":"Uncontrolled Gout","enrollment":11},{"nctId":"NCT06445257","phase":"NA","title":"A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL","status":"RECRUITING","sponsor":"Huai'an First People's Hospital","startDate":"2023-09-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02706951","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-23","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT03864419","phase":"PHASE1","title":"Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-10-24","conditions":"Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma","enrollment":18},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT05839561","phase":"NA","title":"Monotherapy With Letrozole in Tubal Pregnancy","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2020-12-01","conditions":"Tubal Pregnancy Unruptured","enrollment":22},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT02706873","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis","enrollment":1002},{"nctId":"NCT03886038","phase":"PHASE4","title":"Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)","status":"COMPLETED","sponsor":"Region Skane","startDate":"2019-03-15","conditions":"Rheumatoid Arthritis, Healthy Controls","enrollment":142},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT05827497","phase":"PHASE4","title":"Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-04-01","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT05725200","phase":"PHASE2","title":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-09-27","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT04267536","phase":"","title":"An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-02-06","conditions":"Rheumatoid Arthritis (RA)","enrollment":534},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT03492658","phase":"PHASE4","title":"Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2018-05-17","conditions":"Rheumatoid Arthritis, Rheumatic Diseases","enrollment":46},{"nctId":"NCT02177071","phase":"PHASE4","title":"A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2015-10-09","conditions":"Crohn's Disease","enrollment":211},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT02313870","phase":"PHASE3","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-01-22","conditions":"Bullous Pemphigoid","enrollment":322},{"nctId":"NCT05078294","phase":"","title":"Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-08-01","conditions":"Dermatitis, Atopic","enrollment":300},{"nctId":"NCT05090410","phase":"PHASE3","title":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Atsushi Kawakami","startDate":"2021-03-03","conditions":"Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor","enrollment":400},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT02504268","phase":"PHASE3","title":"Effects of Abatacept in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-03","conditions":"Rheumatoid Arthritis","enrollment":994},{"nctId":"NCT02886728","phase":"PHASE3","title":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-08","conditions":"Rheumatoid Arthritis","enrollment":1252},{"nctId":"NCT01578499","phase":"PHASE3","title":"A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-06-11","conditions":"Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma","enrollment":131},{"nctId":"NCT01894516","phase":"PHASE2","title":"Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2013-10-08","conditions":"Rheumatoid Arthritis","enrollment":287},{"nctId":"NCT02814175","phase":"PHASE4","title":"A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-08-05","conditions":"Psoriatic Arthritis","enrollment":246},{"nctId":"NCT02065713","phase":"PHASE3","title":"Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Instituto de Medicina Molecular João Lobo Antunes","startDate":"2014-08","conditions":"Psoriatic Arthritis","enrollment":44},{"nctId":"NCT04540250","phase":"","title":"Stratification of Oral Ulcers in Rheumatoid Arthritis Patients Kept on Methotrexate","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-01","conditions":"Methotrexate Adverse Reaction, Oral Mucositis","enrollment":804},{"nctId":"NCT02608112","phase":"","title":"Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":291},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT01661413","phase":"","title":"Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2012-05-07","conditions":"Acute Leukemia","enrollment":88},{"nctId":"NCT04157010","phase":"PHASE4","title":"Tocilizumab REMission in Early RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT02644499","phase":"PHASE4","title":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":186},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT02287922","phase":"PHASE2","title":"A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT03813771","phase":"PHASE4","title":"Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2019-03","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT01172639","phase":"PHASE4","title":"Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2009-02","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT02313922","phase":"PHASE4","title":"Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2014-11","conditions":"Psoriasis","enrollment":466},{"nctId":"NCT02187055","phase":"PHASE4","title":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Rhematoid Arthritis","enrollment":1152},{"nctId":"NCT00368654","phase":"PHASE1, PHASE2","title":"Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2007-01","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT01007435","phase":"PHASE3","title":"A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":1162},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00299130","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT00109408","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Rheumatoid Arthritis","enrollment":673},{"nctId":"NCT00303563","phase":"PHASE2","title":"A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Rheumatoid Arthritis","enrollment":204},{"nctId":"NCT02693210","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-02","conditions":"Rheumatoid Arthritis","enrollment":161},{"nctId":"NCT01689532","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2012-11","conditions":"Arthritis, Rheumatoid","enrollment":122},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT01548001","phase":"PHASE4","title":"Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":910},{"nctId":"NCT01142726","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT01802593","phase":"PHASE4","title":"Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure","status":"TERMINATED","sponsor":"Prof. Arie Levine","startDate":"2013-02","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT01866150","phase":"","title":"A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":476},{"nctId":"NCT01587989","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01399697","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT02087696","phase":"PHASE4","title":"Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Spanish Foundation of Rheumatology","startDate":"2014-05","conditions":"Arthritis, Rheumatoid","enrollment":122},{"nctId":"NCT00547521","phase":"PHASE3","title":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":119},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":"Psoriasis, Inflammatory Bowel Diseases","enrollment":222},{"nctId":"NCT01120366","phase":"PHASE4","title":"Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation","status":"COMPLETED","sponsor":"SURPRISE Study Group","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":233},{"nctId":"NCT01010503","phase":"PHASE4","title":"A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT01116141","phase":"PHASE2","title":"A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Chelsea Therapeutics","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":250},{"nctId":"NCT01359150","phase":"PHASE2","title":"A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":223},{"nctId":"NCT01040195","phase":"PHASE3","title":"Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2009-06","conditions":"Seronegative Spondyloarthropathies","enrollment":33},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00112034","phase":"PHASE4","title":"AVONEX® Combination Trial - \"ACT\"","status":"COMPLETED","sponsor":"Biogen","startDate":"2003-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":254,"recentPublications":[{"date":"2026 Mar 16","pmid":"41834609","title":"[Idiopathic granulomatous mastitis - a rare inflammatory condition].","journal":"Lakartidningen"},{"date":"2026 Mar 13","pmid":"41825926","title":"Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort.","journal":"RMD open"},{"date":"2026 Feb 21","pmid":"41721120","title":"Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Jan 30","pmid":"41620379","title":"Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis.","journal":"Annals of the rheumatic diseases"},{"date":"2026 Apr","pmid":"41544399","title":"Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials.","journal":"Seminars in arthritis and rheumatism"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methotrexate Monotherapy","genericName":"Methotrexate Monotherapy","companyName":"Bangladesh Medical University","companyId":"bangladesh-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}